Best in Biotech 28 Mar 2024 Are these T cell receptor (TCR) therapy companies on your radar? …and allogeneic candidates as well as antibody-like TCR bispecifics, called T cell Engaging Receptors (TCER). TCERs are biologics that are designed to bind T cells to target and destroy cancer… March 28, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2017 Phase I Results are in for Swedish Biotech’s Cancer Antibody …develops antibody-based immunotherapies to fight cancer. Its pipeline includes clinical and pre-clinical drug candidates, including ADC-1013 and ATOR-1015, as well as novel research candidates. The company has announced that its… November 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2019 CureVac and Genmab Team up to Make Antibody Cancer Drugs out of RNA …could be circumvented by delivering simple mRNA blueprints for antibody drugs into the patient, and turning the patient’s own cells into antibody factories. There are challenges to overcome on the… December 20, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2024 Top biotech deals of October 2024 …arteries restricts blood supply to leg muscles. While financial terms weren’t revealed, the candidate they plan to advance was disclosed. ISM-001 is an antibody designed to neutralize an antibody that… November 4, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2024 Top biotech deals of November 2024 …part of this wintry time. Moreover, biotech deals in antibody-drug conjugates, small molecules, antibody therapies, GLP-1 agonists, and precision medicine stood out in November 2024. Table of contents Top M&As… December 12, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Mar 2025 Top biotech deals of February 2025 …$2.15 billion in milestone payments, with Novartis having paid $925 million upfront. Anthos will hand over its monoclonal antibody program, which is in the clinic to prevent stroke and systemic… March 6, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2016 Can this new Antibody-Drug Conjugate Collaboration make it to the Top? Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs)… October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2025 Top biotech deals in July 2025 …will secure LaNova’s lead candidate, an antibody-drug conjugate (ADC) called LM-302, which is in the clinic to treat gastric cancer and pancreatic ductal adenocarcinoma – the most common type of… August 8, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II …antibody’s efficacy and safety. AC Immune’s anti-Tau monoclonal antibody is based on the company’s SupraAntigen technology. They are generated by injecting the SupraAntigen constructs into mice and selecting antibodies that… November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 4 Feb 2025 World Cancer Day: trends in cancer therapeutics to look forward to in 2025 …the problems faced with getting small molecules to bind to these targets have been addressed, making sotorasib the first KRAS inhibitor to be approved in 2021. Now, candidates like divarasib… February 4, 2025 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 OncoC4 and BioNTech partner in the commercialization of cancer drug candidate German biopharma BioNTech has closed a licensing deal with the U.S.-based clinical-stage company OncoC4 for the development and commercialization of the latter’s lead candidate ONC-392, for the treatment of cancer…. March 23, 2023 - 2 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Aug 2024 Seven companies transforming the biotech industry in Italy …Among them is a vaccine for malaria, which has received significant attention and funding, including $12.2 million from the EU Malaria Fund. Another prominent candidate is MAbCo19, a monoclonal antibody… August 22, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email